AQUALUNG
27.4.2021 11:02:13 CEST | Business Wire | Press release
Aqualung , the leading global designer and manufacturer of dive and water sports gear, today announced the launch of its all new XSCAPE collection. Featuring a 100 percent neoprene-free wetsuit and a rash guard made from sustainable materials, the XSCAPE line is designed for a variety of water activities and reflects Aqualung’s commitment to innovation, ocean discovery and sustainability.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210427005227/en/
Made with Yulex® eco-friendly natural rubber and ultra-stretch fabric, the 4/3mm XSCAPE wetsuit provides enhanced comfort for diving in warm waters or above surface activities in colder temperatures, and can be used for scuba diving, snorkeling, freediving, paddling or a variety of other water sports. The flexible and lightweight XSCAPE wetsuit, available in a red and olive design for men and a tropical-inspired print for women, connects consumers to nature and the natural materials the collection is made from. The suit also features Powertex knee pads, recycled, quick-drying fleece around the torso area to provide additional warmth and comfort, and a reusable mesh bag for storage after use or collecting trash from the beach or water.
“The XSCAPE collection continues Aqualung's legacy in innovation, and their tireless work to create the most forward thinking and eco-conscious dive company in the world,” said Aqualung global ocean ambassador Philippe Cousteau Jr., the grandson of one of Aqualung’s original founders, Captain Jacques-Yves Cousteau. “We all have the power to change the world with the choices we make, and the XSCAPE sets the new standard for wetsuits and rash guards that are stylish, functional and sustainable.”
The new collection’s long-sleeve rash guard for men and women, and matching women’s leggings, offer maximum comfort and breathability and can be used above or below the surface. All rash guards and leggings feature UV protection and are made with polyester fabric sourced from recycled plastic bottles. The entire XSCAPE line comes in plastic-free packaging with hangtags made from recycled cardboard.
“Our aim was to design the ultimate eco-friendly wetsuit that could be used for all kinds of water sports,” said Laurent Boury, Senior Vice President of Brands at Aqualung Group. “Aqualung is committed to using environmentally-friendly materials and processes whenever possible to help reduce our carbon footprint, and we made design choices to ensure the XSCAPE collection was as sustainable as possible.”
“The collection name, XSCAPE, is meant to evoke the feeling of freedom and the quest for wonder that surround exploration, travel and Aqualung’s storied history, including the first ‘aqua-lung’ created by Captain Jacques-Yves Cousteau and engineer Emile Gagnan that made underwater exploration possible,” added Boury.
The XSCAPE collection is available at authorized Aqualung retailers. Inventory may vary by region. To learn more, please visit www.aqualung.com .
About Aqualung Brand
Aqualung, part of the Aqualung Group, is the leading global designer and manufacturer of dive and water sports gear. Now available in more than 100 countries around the world, Aqualung pioneered the creation of modern diving equipment when Captain Jacques-Yves Cousteau teamed with engineer Emile Gagnan in 1943 to develop the first “aqua-lung,” making underwater exploration possible. Aqualung is committed to providing sustainable, innovative, reliable, and easy-to-use products that allow adventure seekers to enjoy responsible water exploration and continues to set the industry standard for water sports equipment in technology, comfort, safety and design. For more information, visit www.aqualung.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210427005227/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 16:00:00 CEST | Press release
IB SmartRouting℠ Routes Orders to the Best Available Price Between KRX and Nextrade Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom